In light of the current revision of the EU general pharmaceuticals legislation, we have today published Recommendations for greener human medicines, which provides recommendations on how the sustainability of human medicinal products on the EU market and pharmaceutical supply chains can be improved.
“There is an urgent need for ambitious legislative and non-legislative measures throughout the life cycle of medicines to minimise the entry of pharmaceutical residues into the environment and reduce risks for human, animal, and environmental health.”
The European Commission is set to propose the revised legislation based on the Pharmaceutical Strategy for Europe in late 2022. This position paper includes 30 policy recommendations focused on three areas:
- Improving the transparency and sustainability of the pharmaceutical supply chain
- Strengthening environmental risk assessments for human medicine
- Encouraging greener medicines, promoting responsible use, and reducing pharmaceutical waste.